Invention Application
- Patent Title: TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
-
Application No.: US17228815Application Date: 2021-04-13
-
Publication No.: US20220119366A1Publication Date: 2022-04-21
- Inventor: Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
- Applicant: ENANTA PHARMACEUTICALS, INC.
- Applicant Address: US MA WATERTOWN
- Assignee: ENANTA PHARMACEUTICALS, INC.
- Current Assignee: ENANTA PHARMACEUTICALS, INC.
- Current Assignee Address: US MA WATERTOWN
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D413/14 ; C07D405/14 ; C07D409/14 ; C07D417/14

Abstract:
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Public/Granted literature
- US11834436B2 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Public/Granted day:2023-12-05
Information query